The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis

• Published in: Frontiers in aging neuroscience Vol. 10; p. 326
• Main Authors: Hipp, Geraldine, Vaillant, Michel, Diederich, Nico J, Roomp, Kirsten, Satagopam, Venkata P, Banda, Peter, Sandt, Estelle, Mommaerts, Kathleen, Schmitz, Sabine K, Longhino, Laura, Schweicher, Alexandra, Hanff, Anne-Marie, Nicolai, Béatrice, Kolber, Pierre, Reiter, Dorothea, Pavelka, Lukas, Binck, Sylvia, Pauly, Claire, Geffers, Lars, Betsou, Fay, Gantenbein, Manon, Klucken, Jochen, Gasser, Thomas, Hu, Michele T, Balling, Rudi, Krüger, Rejko
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 29-10-2018; Frontiers Media S.A
• Subjects: Basal ganglia; Behavior disorders; Biomarkers; Brain diseases; Central nervous system diseases; Clinical trials; Cognition; Cognitive ability; cohort; deep phenotyping; Dementia; Diagnosis; Eye movements; Gait; longitudinal; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Neuroscience; Parkinson's disease; parkinsonism; Patients; Phenotypes; Phenotyping; Sleep; stratification; Luxembourg; Germany; cohort; parkinsonism; longitudinal; stratification; deep phenotyping
• ISSN: 1663-4365; 1663-4365
• DOI: 10.3389/fnagi.2018.00326

While genetic advances have successfully defined part of the complexity in Parkinson's disease (PD), the clinical characterization of phenotypes remains challenging. Therapeutic trials and cohort studies typically include patients with earlier disease stages and exclude comorbidities, thus ignoring a substantial part of the real-world PD population. To account for these limitations, we implemented the Luxembourg PD study as a comprehensive clinical, molecular and device-based approach including patients with typical PD and atypical parkinsonism, irrespective of their disease stage, age, comorbidities, or linguistic background. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, we implemented an open-source digital platform that can be harmonized with international PD cohort studies. Our interests also reflect Luxembourg-specific areas of PD research, including vision, gait, and cognition. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies. We provide evidence for the feasibility of such a cohort program with deep phenotyping and high quality biosampling on parkinsonism in an environment with structural specificities and alert the international research community to our willingness to collaborate with other centers. The combination of advanced clinical phenotyping approaches including device-based assessment will create a comprehensive assessment of the disease and its variants, its interaction with comorbidities and its progression. We envision the Luxembourg Parkinson's study as an important research platform for defining early diagnosis and progression markers that translate into stratified treatment approaches.